Epredia lance des imprimantes à cassettes laser conçues pour améliorer le suivi des échantillons et l'efficacité des laboratoires

Les imprimantes à cassettes laser sont conçues pour améliorer le suivi des échantillons et l'efficacité des laboratoires.

Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523),  and NovaScan, Inc., a company that develops breakthrough technology for cancer detection and stratification, announce that they have signed a letter of intent for a U.S. exclusive commercial distribution agreement for MarginScanTM, a product under development as a medical device designed to support physicians in real-time detection of non-melanoma skin cancer. Epredia has engaged Avantik, a company specializing in supporting diagnostic labs with their operations, to support distribution of this new device to surgeons after it is on the market.

Skin cancer is the most common group of cancers diagnosed worldwide , and it is estimated that one in five Americans will develop skin cancer in their lifetime . Non-melanoma skin cancers (NMSC) are the most common cancers in the United States, affecting more than 3 million Americans a year . Most surgeries for NMSC are simple excisions, which may result in removal of substantial healthy tissue around the suspected cancer. 

MarginScan™ is being designed to address this challenge by supporting Mohs surgery procedures for skin cancer treatment. Mohs Micrographic Surgery (MMS) is an operative method used to detect the presence or absence of a tumor in the margins of a surgical excision. In an MMS procedure, cancer tissue is excised in stages, then flash-frozen and assessed histologically in an onsite lab until clean margins are obtained. Previously, MMS was the only modality for skin cancer treatment that involved comprehensive margin assessment during a procedure. MarginScan™ is being designed to use an electrical assessment to confirm cancer-free margins without the intraoperative histological assessment. This has the potential to allow for faster excisions that spare more healthy tissue, leading to improved outcomes for both patients and clinicians.

With this agreement, Epredia plans to serve as the primary distribution partner of MarginScan™ and have exclusive distribution rights in the United States. Along with distribution, Epredia plans to be responsible for all marketing and commercial activities related to the launch and sale of MarginScan™. After product launch, Epredia will work closely with Avantik to market and sell the new device to Mohs surgeons.

Under these planned arrangements, after launch, MarginScan™ will be the latest addition to Epredia’s world-class portfolio of precision cancer diagnostics products and services that provide a seamless end-to-end laboratory workflow, including slide scanners and printers, cryostats, tissue processors, and consumables such as slides and reagents. In addition to offering MarginScan™, Epredia also has plans to provide consumable products that are used with the device, such as the MarginScan™ electrode and proprietary electrolytic gel used during excisions. 

The two companies anticipate a 2025 U.S. launch for MarginScan™. The planned distribution agreement builds on a previous agreement between NovaScan and PHC Corporation, another subsidiary of PHC Holdings Corporation that is focused on the development and manufacturing of innovative medical testing devices. PHC Holdings Corporation is referred to collectively with its subsidiaries as PHC Group.  

Steven Lynum, President of Epredia, said, “With more than 85 years supporting precision cancer diagnostics, we strive to continuously serve the changing needs of our customers by working with innovative companies like NovaScan to deliver the best solutions. Helping providers make faster, more accurate diagnoses and ultimately improving patient care is what makes this initiative so important.”

Craig Davis, CEO of NovaScan, remarked, “NovaScan is thrilled to be making plans with Epredia to bring MarginScan™ to clinical healthcare providers in the U.S. We will be proud for MarginScan™ to join Epredia’s portfolio of market-leading cancer diagnostics products in the future. We believe that MarginScan™ will play an important role in skin cancer detection and treatment”

Mark Zacur, CEO of Avantik, added, “Our team is continually sourcing the best solutions to expand our portfolio of solutions supporting Mohs clinics with their critical work. We are honored that Epredia selected Avantik as their partner for this planned initiative to bring this breakthrough device to our network of providers and their patients when it is launched.”

---

A propos d'Epredia

Epredia est un leader mondial dans le domaine de l'anatomopathologie.

Epredia est un leader mondial dans le domaine de la pathologie anatomique, fournissant des solutions complètes pour le diagnostic de précision du cancer et le diagnostic des tissus. S'appuyant sur des marques clés telles que Erie Scientific, Menzel-Gläser, Microm, Shandon et Richard-Allan Scientific, le portefeuille d'Epredia comprend des lames de microscope, des instruments et des consommables. Epredia a été créée à la suite de l'acquisition de l'activité de pathologie anatomique de Thermo Fisher Scientific par PHC Holdings en 2019. Epredia est présente sur des sites importants aux États-Unis, au Royaume-Uni, en Allemagne, en Suisse et en Chine, avec un total d'environ 1 200 employés. Epredia s'engage à réaliser sa mission d'améliorer les vies en améliorant les diagnostics de cancer pour les patients du monde entier. Pour plus d'informations sur Epredia et ses produits, veuillez consulter www.epredia.com.

La société Epredia a pour mission d'améliorer les vies en améliorant les diagnostics du cancer pour les patients du monde entier.

A propos de PHC Holdings Corporation (Groupe PHC)

La société PHC Holdings Corporation (Groupe PHC)

PHC Holdings Corporation (TSE 6523) est une entreprise mondiale de soins de santé dont la mission est de contribuer à la santé de la société par le biais de solutions de soins de santé qui ont un impact positif et améliorent la vie des gens. Ses filiales (appelées collectivement PHC Group) comprennent PHC Corporation, Epredia, Ascensia Diabetes Care, LSI Medience Corporation, Mediford et Wemex. Ensemble, ces entreprises développent, fabriquent, vendent et entretiennent des solutions dans les domaines de la gestion du diabète, des solutions de soins de santé, des sciences de la vie et du diagnostic. Les ventes nettes consolidées de PHC Group’étaient de 356,4 milliards de yens pour l’exercice 2022, avec une distribution mondiale de produits et de services dans plus de 125 pays.
www.phchd.com

Pour plus d'informations, veuillez contacter :

Julia Cottran, directrice générale de l'entreprise.
Julia Cottrill
Communication d'entreprise du groupe HPC
Email : julia.cottrill@phchd.com

Julia Cottrill
GroupePHC Communications
Courriel